about
Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment.Serum sonic hedgehog (SHH) and interleukin-(IL-6) as dual prognostic biomarkers in progressive metastatic breast cancer.Comparison of radiation regimens in the treatment of Glioblastoma multiforme: results from a single institution.Elevated ARG1 expression in primary monocytes-derived macrophages as a predictor of radiation-induced acute skin toxicities in early breast cancer patientsIncreased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy.Sensitivity to PRIMA-1MET is associated with decreased MGMT in human glioblastoma cells and glioblastoma stem cells irrespective of p53 statusO6-Methylguanine-DNA methyltransferase is a novel negative effector of invasion in glioblastoma multiforme.MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.Differential response to ablative ionizing radiation in genetically distinct non-small cell lung cancer cells.Antiviral agent Cidofovir restores p53 function and enhances the radiosensitivity in HPV-associated cancers.High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells.A defect in hematopoietic stem cell migration explains the nonrandom X-chromosome inactivation in carriers of Wiskott-Aldrich syndrome.CUX1 Stimulates APE1 Enzymatic Activity and Increases the Resistance of Glioblastoma Cells to the Mono-Alkylating Agent, Temozolomide.Performance of Knowledge-Based Radiation Therapy Planning for the Glioblastoma Disease Site.Response to stereotactic ablative radiotherapy in a novel orthotopic model of non-small cell lung cancer.Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settingsTemozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic OpportunitiesAn integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapyRadiomics in Glioblastoma: Current Status and Challenges Facing Clinical Implementation.Prediction of survival with multi-scale radiomic analysis in glioblastoma patientsMechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to TemozolomideParathyroid Hormone-Related Protein (PTHrP): An Emerging Target in Cancer Progression and MetastasisPTHrP, A Biomarker for CNS Metastasis in Triple-Negative Breast Cancer and Selection for Adjuvant Chemotherapy in Node-Negative DiseaseIntegration of Radiomic and Multi-omic Analyses Predicts Survival of Newly Diagnosed IDH1 Wild-Type Glioblastoma
P50
Q31132069-98298EF8-5726-47BA-957C-ED623F54248BQ33370471-EACAC1D2-A842-42B3-B0B4-0DCBC7CA28FAQ33686729-BA4AAF6A-710E-4373-A8C6-1171A7C0A113Q35575434-EECE4225-E2C2-4637-BB75-32E143A188EFQ36214147-D6A1DBC6-61FD-4E51-890D-956AD2698525Q37355667-02856E2B-348E-4C6C-B882-B5121E847144Q38751430-1DC15AEF-A97D-4DA2-9E77-374DAEE6C5DCQ39276886-0C53FDE8-73B2-4C61-AC07-F5BD5ADF5BB5Q39736118-56E2C9A2-2FAE-48D4-8B9B-4C6C2722E142Q39837257-91F16B84-C59D-4D49-878C-E0589DCDECA1Q40738807-C1DA4298-D45A-4202-8B9F-64FD106F676AQ41830810-931084E6-48E2-42A5-8D48-0061F71D2649Q42485739-C071A9D9-1044-4417-B8F3-170A9056FBCAQ44429187-51C6B9C5-3299-4F73-9961-7816232474EEQ47647202-E582DAB7-7DA8-4EB7-8501-17C339072FACQ48127468-E20496CF-4606-45C5-B4FB-9E802FB1FBE9Q49201909-68044E0F-0C16-4C8F-BECA-F7364A89E8E7Q59329859-D71AE775-7B42-469D-A082-A389F067BDA0Q61800092-C1B3D3F8-4CAF-409C-8788-94489A91E87AQ64057197-561E1B73-7163-4BD8-9EDF-1704527C8B38Q64994466-543F2953-8D4D-432A-8AA1-83845E26FB3AQ89145868-6C612FC2-12AB-4C77-A1F8-2817264BEF2AQ90196572-AC9F3C88-265F-4D7D-99FA-3F5193B0DE1DQ90429903-6808B693-0D72-4808-817C-5DA64F8C51A4Q91976219-E75C4893-FADF-4F4C-8933-69366EF68DDDQ92571056-17A52E57-6075-464C-897D-1B268C7F99BF
P50
description
researcher ORCID ID = 0000-0001-5792-689X
@en
wetenschapper
@nl
name
Siham Sabri
@ast
Siham Sabri
@en
Siham Sabri
@es
Siham Sabri
@nl
type
label
Siham Sabri
@ast
Siham Sabri
@en
Siham Sabri
@es
Siham Sabri
@nl
prefLabel
Siham Sabri
@ast
Siham Sabri
@en
Siham Sabri
@es
Siham Sabri
@nl
P106
P31
P496
0000-0001-5792-689X